# [Document Name] Claims

### [Claim 1]

A compound having the general formula (I) shown below,

# [wherein,

 $R^1$  represents a phenyl group substituted with from 1 to 3 substituents selected from the group consisting of  $C_1$ - $C_4$  alkoxy groups and  $C_1$ - $C_4$  halogenated alkyl groups;  $R^2$  represents a phenyl group substituted with from 1 to 3 halogen atoms;  $R^3$  represents a phenyl group substituted with a halogen atom or a nitro group; D represents an oxygen atom or a methylene group, and n represents an integer of 0 or 1).

# [Claim 2]

A compound according to Claim 1, wherein R<sup>1</sup> is 3-isopropyloxy, 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

### [Claim 3]

A compound according to Claim 1, wherein R<sup>1</sup> is 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

#### [Claim 4]

A compound according to any one claim selected from Claims 1 to 3, wherein  $R^2$  is a phenyl group substituted with 1 or 2 fluorine atoms or chlorine atoms.

### [Claim 5]

A compound according to any one claim selected from Claims 1 to 3, wherein R<sup>2</sup> is 3,4-dichlorophenyl.

### [Claim 6]

A compound according to any one claim selected from Claims 1 to 5, wherein D is an oxygen atom.

### [Claim 7]

A compound according to any one claim selected from Claims 1 to 6, wherein n is 0.

# [Claim 8]

A compound according to Claim 1, wherein R<sup>1</sup> is 3-isopropyloxy, D is a methylene group, and n is 1.

## [Claim 9]

A compound according to any one claim selected from Claims 1 to 8, wherein R<sup>3</sup> is a phenyl group substituted with a chlorine atom or a nitro group.

# [Claim 10]

A compound according to Claim 1, wherein said compound is any one of the compounds listed below:

- 2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4chlorobenzenesulfonate,
- 2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,
- 2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- 2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate.

- 2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- 2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,
- 2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- 2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,
- 2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,
- 2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,
- 2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,
- 2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate, and
- 2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate.

### [Claim 11]

A compound according to Claim 1, wherein said compound is any one of the compounds listed below:

- 2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- 2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate, and
- 2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate.

## [Claim 12]

A compound, having an enantiomeric excess which is substantially 100%, having the general formula (I') or (I'') shown below,

$$\mathbb{R}^{3} \mathbb{S} = \mathbb{R}^{2} \mathbb{R}^{1}$$

$$\mathbb{R}^{1} \mathbb{R}^{1}$$

$$\mathbb{R}^{1} \mathbb{R}^{1} \mathbb{R}^{$$

# (wherein

 $R^1$  represents a phenyl group substituted with from 1 to 3 substituents selected from the group consisting of  $C_1$ - $C_4$  alkoxy groups and  $C_1$ - $C_4$  halogenated alkyl groups;  $R^2$  represents a phenyl group substituted with from 1 to 3 halogen atoms;  $R^3$  represents a phenyl group substituted with a halogen atom or a nitro group;

D represents an oxygen atom or a methylene group; and n represents an integer of 0 or 1).

# [Claim 13]

A compound according to Claim 12, wherein R<sup>1</sup> is 3-isopropyloxy, 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

### [Claim 14]

A compound according to Claim 12, wherein R<sup>1</sup> is 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

### [Claim 15]

A compound according to any one claim selected from Claims 12 to 14, wherein R<sup>2</sup> is a phenyl group substituted with 1 or 2 fluorine atoms or chlorine atoms.

### [Claim 16]

A compound according to any one claim selected from Claims 12 to 14, wherein R<sup>2</sup> is 3,4-dichlorophenyl.

### [Claim 17]

A compound according to any one claim selected from Claims 12 to 16, wherein D is an oxygen atom.

## [Claim 18]

A compound according to any one claim selected from Claims 12 to 17, wherein n is 0.

# [Claim 19]

A compound according to Claim 12, wherein R<sup>1</sup> is 3-isopropyloxy, D is a methylene group, and n is 1.

# [Claim 20]

A compound according to any one claim selected from Claims 12 to 19, wherein R<sup>3</sup> is a phenyl group substituted with a chlorine atom or a nitro group.

#### [Claim 21]

A compound according to any one claim selected from Claims 12 to 20, having the general formula (I').

### [Claim 22]

A compound according to Claim 12, wherein said compound is any one of the compounds listed below:

- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,
- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yllethyl 4-nitrobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,
- (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,

- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate, and
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate.

### [Claim 23]

A compound according to Claim 12, wherein said compound is any one of the compounds listed below:

- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[3-[3,5-bis(trifluoromethyl)benzoyl]-1-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate, and

• (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate.

# [Claim 24]

A method for obtaining a compound, having an enantiomeric excess which is substantially 100%, having the general formula (I') or (I'') by crystallizing a mixture of a compound having the general formula (I') and a compound having the general formula (I''):

(in the general formulae (I') and (I''),

 $R^1$  represents a phenyl group substituted with 1 to 3 groups selected from the group consisting of  $C_1$ - $C_4$  alkoxy groups and  $C_1$ - $C_4$  halogenated alkyl groups;

R<sup>2</sup> represents a phenyl group substituted with 1 to 3 halogen atoms;

 $R^3$  represents a  $C_1$ - $C_4$  alkyl group, a phenyl group, or a phenyl group substituted with a  $C_1$ - $C_4$  alkyl group, a halogen atom or a nitro group;

D represents an oxygen atom or a methylene group; and n represents an integer of 0 or 1).

#### [Claim 25]

A method according to Claim 24, wherein R<sup>1</sup> is 3-isopropyloxy, 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

# [Claim 26]

A method according to Claim 24, wherein R<sup>1</sup> is 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

## [Claim 27]

A method according to any one claim selected from Claims 24 to 26, wherein R<sup>2</sup> is a phenyl group substituted with 1 or 2 fluorine atoms or chlorine atoms.

### [Claim 28]

A method according to any one claim selected from Claims 24 to 26, wherein R<sup>2</sup> is 3,4-dichlorophenyl.

### [Claim 29]

A method according to any one claim selected from Claims 24 to 28, wherein R<sup>3</sup> is a methyl group, a phenyl group, or a phenyl group substituted with a methyl group, a chlorine atom or a nitro group.

## [Claim 30]

A method according to any one claim selected from Claims 24 to 29, wherein D is an oxygen atom.

## [Claim 31]

A method according to any one claim selected from Claims 24 to 30, wherein n is 0.

# [Claim 32]

A method according to Claim 24, wherein R<sup>1</sup> is 3-isopropyloxyphenyl, D is a methylene group, and n is 1.

# [Claim 33]

A method according to any one claim selected from Claims 24 to 32, wherein R<sup>3</sup> is a phenyl group substituted with a chlorine atom or a nitro group.

# [Claim 34]

A method according to any one claim selected from Claims 24 to 33, for obtaining a compound, having an enantiomeric excess which is substantially 100%, having the general formula (I').

### [Claim 35]

A method according to Claim 24, for obtaining any one of the compounds listed below:

- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,
- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-methylbenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl benzenesulfonate,
- (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl]morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-methylbenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,

- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-methylbenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl benzenesulfonate,
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate, and
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-methylbenzenesulfonate.

# [Claim 36]

A method according to Claim 24, for obtaining any one of the compounds listed below:

- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,

- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate, and
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)pipelidin-3-yl]ethyl 4-chlorobenzenesulfonate.

### [Claim 37]

A method for preparing compounds having general formula (III) shown below or pharmaceutically acceptable salts thereof, which is characterized by reacting a compound having general formula (I') shown below with a compound having general formula (II) shown below:

$$\mathbb{R}^{3} \longrightarrow \mathbb{R}^{0} \longrightarrow \mathbb{R}^{2} \longrightarrow \mathbb{R}^{1} \longrightarrow \mathbb{R}^{1}$$

(wherein  $R^1$  represents a phenyl group substituted with 1 to 3 substituents selected from a group consisting of  $C_1$ - $C_4$  alkoxy groups and  $C_1$ - $C_4$  halogenated alkyl groups;  $R^2$  represents a phenyl group substituted with 1 to 3 halogen atoms;  $R^3$  represents a phenyl group or a phenyl group substituted with a  $C_1$ - $C_4$  alkyl group, a halogen atom or a nitro group; D represents an oxygen atom or a methylene group; and n represents an integer of 0 or 1),

(wherein G represents a >C-OH group or a >S $\rightarrow$ O group), and

$$\begin{array}{c|c}
R^2 & O \\
N & O \\
N$$

(wherein D, G, R<sup>1</sup>, R<sup>2</sup> and n have the same meanings as those indicated hereinbefore).

# [Claim 38]

A method according to Claim 37, wherein R<sup>1</sup> is 3-isopropyloxyphenyl, 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

## [Claim 39]

A method according to Claim 37, wherein R<sup>1</sup> is 3,4,5-trimethoxyphenyl or 3,5-bis(trifluoromethyl)phenyl.

# [Claim 40]

A method according to any one claim selected from Claims 37 to 39, wherein R<sup>2</sup> is a phenyl group substituted with 1 or 2 fluorine atoms or chlorine atoms.

# [Claim 41]

A method according to any one claim selected from Claims 37 to 39, wherein R<sup>2</sup> is 3,4-dichlorophenyl.

### [Claim 42]

A method according to any one claim selected from Claims 37 to 41, wherein R<sup>3</sup> is a phenyl group, or a phenyl group substituted with a methyl group, a chlorine atom or a nitro group.

## [Claim 43]

A method according to any one claim selected from Claims 37 to 42, wherein D is an oxygen atom.

### [Claim 44]

A method according to any one claim selected from Claims 37 to 43, wherein n is 0.

# [Claim 45]

A method according to Claim 37, wherein R<sup>1</sup> is 3-isopropyloxyphenyl, D is a methylene group, and n is 1.

### [Claim 46]

A method according to any one claim selected from Claims 37 to 45, wherein R<sup>3</sup> is a phenyl group substituted with a chlorine atom or a nitro group.

# [Claim 47]

A method according to Claim 37, wherein the compound having general formula (I') is any one of the compounds listed below:

- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,
- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-methylbenzenesulfonate,
- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl benzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,

- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-methylbenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl benzenesulfonate,
- (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-nitrobenzenesulfonate,
- (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 2-nitrobenzenesulfonate,
- (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-methylbenzenesulfonate,
- (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl benzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-methylbenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl benzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,

- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-methylbenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl benzenesulfonate,
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-nitrobenzenesulfonate,
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 2-nitrobenzenesulfonate,
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-methylbenzenesulfonate, and
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl benzenesulfonate.

# [Claim 48]

A method according to Claim 37, wherein the compound having general formula (I') is any one of the compounds listed below:

- (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (2R)-2-[4-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate,
- (+)-2-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate, and
- (+)-2-[1-{[3,5-bis(trifluoromethyl)phenyl]acetyl}-3-(3,4-dichlorophenyl)piperidin-3-yl]ethyl 4-chlorobenzenesulfonate.

S:/Chemical/Sankyo/FP0505/FP0505s